Literature DB >> 26901287

Multifunctional nanoparticles for cancer immunotherapy.

Tayebeh Saleh1, Seyed Abbas Shojaosadati2.   

Abstract

During the last decades significant progress has been made in the field of cancer immunotherapy. However, cancer vaccines have not been successful in clinical trials due to poor immunogenicity of antigen, limitations of safety associated with traditional systemic delivery as well as the complex regulation of the immune system in tumor microenvironment. In recent years, nanotechnology-based delivery systems have attracted great interest in the field of immunotherapy since they provide new opportunities to fight the cancer. In particular, for delivery of cancer vaccines, multifunctional nanoparticles present many advantages such as targeted delivery to immune cells, co-delivery of therapeutic agents, reduced adverse outcomes, blocked immune checkpoint molecules, and amplify immune activation via the use of stimuli-responsive or immunostimulatory materials. In this review article, we highlight recent progress and future promise of multifunctional nanoparticles that have been applied to enhance the efficiency of cancer vaccines.

Entities:  

Keywords:  cancer vaccine; delivery system; immunotherapy; multifunctional nanoparticle; tumor microenvironment

Mesh:

Substances:

Year:  2016        PMID: 26901287      PMCID: PMC4964832          DOI: 10.1080/21645515.2016.1147635

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  84 in total

1.  Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells.

Authors:  P J Pussinen; H Lindner; O Glatter; H Reicher; G M Kostner; A Wintersperger; E Malle; W Sattler
Journal:  Biochim Biophys Acta       Date:  2000-05-31

2.  Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells.

Authors:  Federica Simeoni; May C Morris; Frederic Heitz; Gilles Divita
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

3.  Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Science       Date:  2003-01-16       Impact factor: 47.728

Review 4.  Dendritic cell-based cancer immunotherapy.

Authors:  Edgar G Engleman
Journal:  Semin Oncol       Date:  2003-06       Impact factor: 4.929

Review 5.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

6.  Immune surveillance against a solid tumor fails because of immunological ignorance.

Authors:  A F Ochsenbein; P Klenerman; U Karrer; B Ludewig; M Pericin; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses.

Authors:  John Dileo; Rajkumar Banerjee; Mark Whitmore; Jayakar V Nayak; Louis D Falo; Leaf Huang
Journal:  Mol Ther       Date:  2003-05       Impact factor: 11.454

8.  Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.

Authors:  Julia A Brown; David M Dorfman; Feng-Rong Ma; Elizabeth L Sullivan; Oliver Munoz; Clive R Wood; Edward A Greenfield; Gordon J Freeman
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

9.  Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.

Authors:  Christina L van Broekhoven; Christopher R Parish; Caroline Demangel; Warwick J Britton; Joseph G Altin
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

10.  Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor.

Authors:  Zhengrong Cui; Su-Ji Han; Leaf Huang
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

View more
  11 in total

1.  Nanoparticle Design Strategies for Effective Cancer Immunotherapy.

Authors:  Praveena Velpurisiva; Aniket Gad; Brandon Piel; Rahul Jadia; Prakash Rai
Journal:  J Biomed (Syd)       Date:  2017

2.  Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.

Authors:  Hua Li; Shengwen Shao; Jianshu Cai; Danielle Burner; Lingeng Lu; Qiuqiang Chen; Boris Minev; Wenxue Ma
Journal:  Immunology       Date:  2017-07-27       Impact factor: 7.397

3.  Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.

Authors:  Hamilton Kakwere; Elizabeth S Ingham; Riley Allen; Lisa M Mahakian; Sarah M Tam; Hua Zhang; Matthew T Silvestrini; Jamal S Lewis; Katherine W Ferrara
Journal:  Bioconjug Chem       Date:  2017-10-13       Impact factor: 4.774

Review 4.  Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes.

Authors:  Erika Dosekova; Jaroslav Filip; Tomas Bertok; Peter Both; Peter Kasak; Jan Tkac
Journal:  Med Res Rev       Date:  2016-11-15       Impact factor: 12.944

5.  Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles.

Authors:  Zeting Yuan; Guohua Fan; Honglei Wu; Chaolian Liu; Yueping Zhan; Yanyan Qiu; Chenting Shou; Feng Gao; Jun Zhang; Peihao Yin; Ke Xu
Journal:  Mol Ther       Date:  2021-05-21       Impact factor: 12.910

Review 6.  Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.

Authors:  Charles B Chesson; Andrew Zloza
Journal:  Nanomedicine (Lond)       Date:  2017-11-03       Impact factor: 5.307

Review 7.  Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?

Authors:  Purushottam Lamichhane; Neha P Amin; Manuj Agarwal; Narottam Lamichhane
Journal:  Medicines (Basel)       Date:  2018-10-23

Review 8.  Emerging Prospects for Nanoparticle-Enabled Cancer Immunotherapy.

Authors:  Manal Ali Buabeid; El-Shaimaa A Arafa; Ghulam Murtaza
Journal:  J Immunol Res       Date:  2020-01-03       Impact factor: 4.818

Review 9.  Nanoparticle cancer vaccines: Design considerations and recent advances.

Authors:  Jingjing Liu; Lei Miao; Jiying Sui; Yanyun Hao; Guihua Huang
Journal:  Asian J Pharm Sci       Date:  2019-12-31       Impact factor: 6.598

Review 10.  Nucleic Acid-Based Approaches for Tumor Therapy.

Authors:  Simone Hager; Frederic Julien Fittler; Ernst Wagner; Matthias Bros
Journal:  Cells       Date:  2020-09-09       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.